BACKGROUND: PTEN is well known to function as a tumor suppressor that antagonizes oncogenic signaling and maintains genomic stability. The PTEN gene is frequently deleted or mutated in human cancers and the wide cancer spectrum associated with PTEN deficiency has been recapitulated in a variety of mouse models of Pten deletion or mutation. Pten mutations are highly penetrant in causing various types of spontaneous tumors that often exhibit resistance to anticancer therapies including immunotherapy. Recent studies demonstrate that PTEN also regulates immune functionality. OBJECTIVE: To understand the multifaceted functions of PTEN as both a tumor suppressor and an immune regulator. METHODS: This review will summarize the emerging knowledge of PTEN function in cancer immunoediting. In addition, the mechanisms underlying functional integration of various PTEN pathways in regulating cancer evolution and tumor immunity will be highlighted. RESULTS: Recent preclinical and clinical studies revealed the essential role of PTEN in maintaining immune homeostasis, which significantly expands the repertoire of PTEN functions. Mechanistically, aberrant PTEN signaling alters the interplay between the immune system and tumors, leading to immunosuppression and tumor escape. CONCLUSION: Rational design of personalized anti-cancer treatment requires mechanistic understanding of diverse PTEN signaling pathways in modulation of the crosstalk between tumor and immune cells.
BACKGROUND:PTEN is well known to function as a tumor suppressor that antagonizes oncogenic signaling and maintains genomic stability. The PTEN gene is frequently deleted or mutated in humancancers and the wide cancer spectrum associated with PTEN deficiency has been recapitulated in a variety of mouse models of Pten deletion or mutation. Pten mutations are highly penetrant in causing various types of spontaneous tumors that often exhibit resistance to anticancer therapies including immunotherapy. Recent studies demonstrate that PTEN also regulates immune functionality. OBJECTIVE: To understand the multifaceted functions of PTEN as both a tumor suppressor and an immune regulator. METHODS: This review will summarize the emerging knowledge of PTEN function in cancer immunoediting. In addition, the mechanisms underlying functional integration of various PTEN pathways in regulating cancer evolution and tumor immunity will be highlighted. RESULTS: Recent preclinical and clinical studies revealed the essential role of PTEN in maintaining immune homeostasis, which significantly expands the repertoire of PTEN functions. Mechanistically, aberrant PTEN signaling alters the interplay between the immune system and tumors, leading to immunosuppression and tumor escape. CONCLUSION: Rational design of personalized anti-cancer treatment requires mechanistic understanding of diverse PTEN signaling pathways in modulation of the crosstalk between tumor and immune cells.
Entities:
Keywords:
PTEN; epigenome; genome; metabolism; phosphoinositide 3-kinase; regulatory T cells
Authors: Ana Ortega-Molina; Alejo Efeyan; Elena Lopez-Guadamillas; Maribel Muñoz-Martin; Gonzalo Gómez-López; Marta Cañamero; Francisca Mulero; Joaquin Pastor; Sonia Martinez; Eduardo Romanos; M Mar Gonzalez-Barroso; Eduardo Rial; Angela M Valverde; James R Bischoff; Manuel Serrano Journal: Cell Metab Date: 2012-03-07 Impact factor: 27.287
Authors: Weiming Ouyang; Will Liao; Chong T Luo; Na Yin; Morgan Huse; Myoungjoo V Kim; Min Peng; Pamela Chan; Qian Ma; Yifan Mo; Dies Meijer; Keji Zhao; Alexander Y Rudensky; Gurinder Atwal; Michael Q Zhang; Ming O Li Journal: Nature Date: 2012-11-07 Impact factor: 49.962
Authors: Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo Journal: Nat Med Date: 2016-07-04 Impact factor: 53.440
Authors: Dimitri G Trembath; Anastasia Ivanova; Michal T Krauze; John M Kirkwood; Nana Nikolaishvilli-Feinberg; Stergios J Moschos Journal: Melanoma Res Date: 2021-06-01 Impact factor: 3.199
Authors: Alain P Algazi; Christopher G Twitty; Katy K Tsai; Mai Le; Robert Pierce; Erica Browning; Reneta Hermiz; David A Canton; Donna Bannavong; Arielle Oglesby; Murray Francisco; Lawrence Fong; Mikael J Pittet; Sean P Arlauckas; Christopher Garris; Lauren P Levine; Carlos Bifulco; Carmen Ballesteros-Merino; Shailender Bhatia; Sharron Gargosky; Robert H I Andtbacka; Bernard A Fox; Michael D Rosenblum; Adil I Daud Journal: Clin Cancer Res Date: 2020-05-06 Impact factor: 13.801